A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

Join Dr. Srinivas K G, Dr. Abhaya Kumar S M, and Dr. Vishwanath S in a panel discussion on clinical trial endpoints for tumors with PPS > 12 months.

Speakers : Dr. Srinivas K G , Dr. Abhaya Kumar SM , Dr. Vishwanath S

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

Discover real-world clinical outcomes, key findings, and expert insights for optimizing patient care. Watch now for evidence-based oncology perspectives!

Speakers : Dr. Srinivas K G

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

Explore expert insights from Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja on the latest treatment strategies for relapsed/refractory adult B-cell ALL.

Speakers : Dr. Pawan Kumar Singh ,Dr. Roshan Dixit ,Dr. Manisha Jain ,Dr. Avruti Baweja

Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL

Renowned experts Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja discuss treatment goals for relapsed adult B-cell ALL, covering immunotherapy, targeted therapies,

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Avriti Baveja

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?

Learn about CAR T-cell therapy, bispecific antibodies, and personalized treatment strategies. Watch now for cutting-edge recommendations!

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Avriti Baveja

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

Explore expert insights from Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja on Iontuzumab’s impact on CR/CRi rates and MRD negativity in leukemia.

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Roshan Dikshit , Dr. Avriti Baveja

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

Explore the long-term survival outcomes of iontuzumab-treated patients in the INO-VATE trial with experts Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja.

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Avriti Baveja

Cost Burden/ Burden of Hospitalization For R/R ALL Patients

Explore expert insights from Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja on the cost and hospitalization burden for R/R ALL patients.

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Avriti Baveja

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

In this webinar, a detailed discussion is done on Expert group convenes to discuss management strategies for EGFR mutation-positive NSCLC.

Speakers : Dr. Vineet Govinda Gupta ( Moderator ) ,Dr. Atul Sharma ( Panelist ) ,Dr. Abhishek Bansal ( Panelist )

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

Expert meeting discussing management strategies and therapies for EGFR mutation-positive non-small cell lung cancer.

Speakers : Dr. Abhishek Bansal ( Panelist ) ,Dr. Atul Sharma ( Panelist ) ,Dr. Vineet Govinda Gupta ( Moderator )


Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study opens up possibility of bespoke prostate cancer treatment

2.

Why Encouragement May Not Improve Motivation in Depression

3.

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients

4.

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

5.

Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot